Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660732 · ClinicalTrials.gov registry record · Phase 2
Rilonacept in Subjects With Cardiac Sarcoidosis
A Phase 2 study of Cardiac Sarcoidosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT06660732: Recruiting Phase 2 study of Cardiac Sarcoidosis, sponsored by Mayo Clinic.
NCT06660732 is a Phase 2 study of Cardiac Sarcoidosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 83-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660732, a Phase 2 study of Cardiac Sarcoidosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
Primary Outcome
Fluorodeoxyglucose F18 uptake is evaluated across a 17 segment heart model. A higher number indicates higher myocardial inflammatory activity, while a lower number indicates lower inflammatory activity
Conditions Studied
Interventions
- DRUG Rilonacept
Study Locations (2)
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What NCT06660732 shows while recruiting
NCT06660732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 83-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Cardiac Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Rilonacept is the first listed.
NCT06660732 reports a single indexed study location in Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06660732 about?
NCT06660732 is a clinical study titled "Rilonacept in Subjects With Cardiac Sarcoidosis". The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.
What is the current status of trial NCT06660732?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-05. Estimated completion is 2027-03.
What conditions does trial NCT06660732 study?
This clinical trial studies the following conditions: Cardiac Sarcoidosis.
What interventions are being tested in trial NCT06660732?
The interventions under investigation include: Rilonacept (DRUG).
Who is sponsoring clinical trial NCT06660732?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660732 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI